Gingivitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 - PowerPoint PPT Presentation

About This Presentation
Title:

Gingivitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Description:

The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s report also highlights the patent, patent exclusivity information and competitive landscape. – PowerPoint PPT presentation

Number of Views:32

less

Transcript and Presenter's Notes

Title: Gingivitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015


1
Gingivitis-Global API Manufacturers, Marketed
and Phase III Drugs Landscape, 2015
2
Summary
Gingivitis-API Insights, 2015,report provides
Gingivitis drugs marketed details and API
Manufacturers details across the globe along with
the location. The report gives the clear idea on
the United States Drug Master File (USDMF) and
Europe DMF filed by worldwide countries related
to the drugs falling under Gingivitis. The Report
provides the India and China API Manufactures who
are driving the current API Market.
DelveInsights report also highlights the patent,
patent exclusivity information and competitive
landscape.The research analysis also presents
the global sales forecasts data for the
Gingivitis drugs till 2016.The active
pharmaceutical ingredients worldwide market is in
continuous development from the recent years.
There is expected to be a major impact on the
global API industry, with the large number of
blockbuster drugs going off patent in the coming
years. It is going to affect the revenue of the
API market as generic drugs occupy the market.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
3
India and China produce a large percentage of a
majority of the APIs and intermediates produced
in the world currently. The USFDA and EMA have
strict guidelines for API manufacturing 'Process
Validation General Principles and Practices'.
While countries such as Japan and Singapore are
signatories to the ICH Q7 regulation, India and
China follow their national GMP guidelines. The
efficiency and expertise of Asian contract
manufacturers have positioned them in a very
strategic space in the global pharmaceutical
supply chain, with a vast majority of the APIs
and intermediates being sourced from markets such
as India and China.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
4
Data SourcesThe report is built using data and
information sourced from proprietary databases,
primary and secondary research and in-house
analysis by DelveInsight team of industry
experts.Secondary sources information and data
has been collected from various printable and
non-printable sources like search engines, News
websites, Government Websites, Trade Journals,
White papers, Magazines, Trade associations,
Books, Industry Portals, Industry Associations
and access to available databases.Note
Certain sections in the report may be removed or
altered based on the availability and relevance
of data for the indicated disease.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
5
Scope A snapshot of the global Market
therapeutics scenario for Gingivitis. A review
of the marketed products under prescription for
Gingivitis, regulatory information and marketing
status. Coverage of global patent coverage and
detailed commentaries on the US patent
challenges. Graphical representation of
investigational products for patent expiry and
market exclusivities across the globe. Product
profiles for marketed products for Gingivitis
with complete description of mechanism of action,
therapeutic class, target, route(s) of
administration and chemical details. Coverage
of API Manufacturers for Gingivitis drugs in the
United States, Europe and Asian Regions with
location details. Coverage of Regulatory
filings in the US, Europe, and Asia specifically
India and China for Gingivitis drugs. Key
discontinued Marketed products. Global Sales
Figure from 2012-2016.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
6
Reasons to Buy Evaluate the marketing status
and exclusivity details of Gingivitis key
products to exploit opportunities for generic
drug development opportunities. Key players in
the pharmaceutical industry.Strategic drivers
and restraints of this market are revealed and
market opportunities and challenges are
identified. Design effective counter-strategies
to gain competitive advantage by identifying the
key patent expiry details and exclusivity with
respect to Gingivitis. API intelligence over
marketed drugs for Gingivitis and gaining primary
intelligence over active ingredients
manufacturers across the globe. Uncovering
opportunities in the rapidly growing the US
markets.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
7
Table of Contents
  1. Indication Overview
  2. Marketed Drugs Assessment
  3. Marketed Details of Drugs by Application Type
  4. Marketed Details of Drugs (NDA) by Marketing
    Status
  5. Marketed Details of Drugs by Patent Expiration
    Timeline
  6. The Active Pharmaceutical Ingredient (API)
    Manufacturers Assessment
  7. The API Manufacturers by the United States Drug
    Master File (US DMF) Status.
  8. The API Manufacturers by the US DMF Status (Drug
    Specific)
  9. Drugs Market Data and Forecasted Sales Figures
    (2012-2016)

W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
8
To view the full Executive Summary and Table of
Contents, please visit Gingivitis-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015 Contact Us-Call India
91-22-27810772/73Email id info_at_bharatbook.com
Website www.bharatbook.com Our Blog
https//www.bharatbook.com/blog/
Follow Us On
Write a Comment
User Comments (0)
About PowerShow.com